{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T18:27:32Z","timestamp":1788546452662,"version":"build-2803163510"},"reference-count":61,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Continuum"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1212\/con.0000000000000745","type":"journal-article","created":{"date-parts":[[2019,6,3]],"date-time":"2019-06-03T14:16:02Z","timestamp":1559571362000},"page":"773-792","source":"Crossref","is-referenced-by-count":46,"title":["Pregnancy and Family Planning in Multiple Sclerosis"],"prefix":"10.1212","volume":"25","author":[{"given":"Annette M.","family":"Langer-Gould","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318224afc9"},{"key":"e_1_3_1_3_2","unstructured":"Smith J Leimpeter A Albers K. Vitamin D and postpartum multiple sclerosis relapses. Poster presented at: 70th American Academy of Neurology Annual Meeting; April 21\u201327 2018; Los Angeles CA."},{"issue":"8","key":"e_1_3_1_4_2","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1001\/archneurol.2009.132","article-title":"Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis","volume":"66","author":"Langer-Gould A","year":"2009","unstructured":"Langer-Gould A Huang SM Gupta R. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol 2009;66(8):958\u2013963. doi:10.1001\/archneurol.2009.132.","journal-title":"Arch Neurol"},{"issue":"10","key":"e_1_3_1_5_2","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2015.1806","article-title":"Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses","volume":"72","author":"Hellwig K","year":"2015","unstructured":"Hellwig K Rockhoff M Herbstritt S. Exclusive breastfeeding and the effect on postpartum multiple sclerosis relapses. JAMA Neurol 2015;72(10):1132\u20131138. doi:10.1001\/jamaneurol.2015.1806.","journal-title":"JAMA Neurol"},{"key":"e_1_3_1_6_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24682"},{"issue":"5","key":"e_1_3_1_7_2","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1056\/NEJM199807303390501","article-title":"Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group","volume":"339","author":"Confavreux C","year":"1998","unstructured":"Confavreux C Hutchinson M Hours MM. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998;339(5):285\u2013291. doi:10.1056\/NEJM199807303390501.","journal-title":"N Engl J Med"},{"issue":"7649","key":"e_1_3_1_8_2","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1136\/bmj.39521.566296.BE","article-title":"Breast feeding","volume":"336","author":"Hoddinott P","year":"2008","unstructured":"Hoddinott P Tappin D Wright C. Breast feeding. BMJ 2008;336(7649):881\u2013887. doi:10.1136\/bmj.39521.566296.BE.","journal-title":"BMJ"},{"issue":"5","key":"e_1_3_1_9_2","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1136\/annrheumdis-2015-208840","article-title":"The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation","volume":"75","author":"G\u00f6testam Skorpen C","year":"2016","unstructured":"G\u00f6testam Skorpen C Hoeltzenbein M Tincani A. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016;75(5):795\u2013810. doi:10.1136\/annrheumdis-2015-208840.","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"e_1_3_1_10_2","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaneurol.2014.209","article-title":"Natalizumab use during the third trimester of pregnancy","volume":"71","author":"Haghikia A","year":"2014","unstructured":"Haghikia A Langer-Gould A Rellensmann G. Natalizumab use during the third trimester of pregnancy. JAMA Neurol 2014;71(7):891\u2013895. doi:10.1001\/jamaneurol.2014.209.","journal-title":"JAMA Neurol"},{"key":"e_1_3_1_11_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517731913"},{"key":"e_1_3_1_12_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000377"},{"key":"e_1_3_1_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000000541"},{"issue":"2","key":"e_1_3_1_14_2","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/CPJ.0000000000000436","article-title":"Multiple sclerosis management and reproductive changes: a guide for general neurologists","volume":"8","author":"Kaisey M","year":"2018","unstructured":"Kaisey M Sicotte N Giesser B. Multiple sclerosis management and reproductive changes: a guide for general neurologists. Neurol Clin Pract 2018;8(2):142\u2013147. doi:10.1212\/CPJ.0000000000000436.","journal-title":"Neurol Clin Pract"},{"issue":"8","key":"e_1_3_1_15_2","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1212\/WNL.0000000000000155","article-title":"The pill times 2: what every woman with multiple sclerosis should know","volume":"82","author":"Langer-Gould AM","year":"2014","unstructured":"Langer-Gould AM. The pill times 2: what every woman with multiple sclerosis should know. Neurology 2014;82(8):654\u2013655. doi:10.1212\/WNL.0000000000000155.","journal-title":"Neurology"},{"issue":"12","key":"e_1_3_1_16_2","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1001\/archneur.63.12.1686","article-title":"Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review","volume":"63","author":"Langer-Gould A","year":"2006","unstructured":"Langer-Gould A Popat RA Huang SM. Clinical and demographic predictors of long-term disability in patients with relapsing-remitting multiple sclerosis: a systematic review. Arch Neurol 2006;63(12):1686\u20131691. doi:10.1001\/archneur.63.12.1686.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_17_2","volume-title":"Pregnancy-related relapses in a large, contemporary multiple sclerosis cohort: no increased risk in the postpartum period","author":"Langer-Gould AM","unstructured":"Langer-Gould AM Smith J Albers K. Pregnancy-related relapses in a large, contemporary multiple sclerosis cohort: no increased risk in the postpartum period. In: Proceedings of the 71st Annual Meeting of the American Academy of Neurology; May 4\u201310, 2019; Philadelphia, PA."},{"key":"e_1_3_1_18_2","unstructured":"Aubagio (teriflunomide) [package insert]. Cambridge MA; Sanofi Genzyme; 2012."},{"issue":"1","key":"e_1_3_1_19_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7224\/1537-2073.2016-079","article-title":"Pregnancy outcomes from the branded glatiramer acetate pregnancy database","volume":"20","author":"Sandberg-Wollheim M","year":"2018","unstructured":"Sandberg-Wollheim M Neudorfer O Grinspan A. Pregnancy outcomes from the branded glatiramer acetate pregnancy database. Int J MS Care 2018;20(1):9\u201314. doi:10.7224\/1537-2073.2016-079.","journal-title":"Int J MS Care"},{"issue":"11","key":"e_1_3_1_20_2","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1212\/WNL.0b013e3182698c64","article-title":"Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review","volume":"79","author":"Lu E","year":"2012","unstructured":"Lu E Wang BW Guimond C. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology 2012;79(11):1130\u20131135. doi:10.1212\/WNL.0b013e3182698c64.","journal-title":"Neurology"},{"key":"e_1_3_1_21_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458516634872"},{"key":"e_1_3_1_22_2","unstructured":"Everage NJ Liu S Yun J. Pregnancy outcomes with delayed-release dimethyl fumarate: interim results from an International Registry. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Online Library 2017. onlinelibrary.ectrims-congress.eu\/ectrims\/2017\/ACTRIMS-ECTRIMS2017\/199756\/nicholas.j.everage.pregnancy.outcomes.with.delayed-release.dimethyl.fumarate.html. Accessed April 4 2019."},{"key":"e_1_3_1_23_2","unstructured":"Center for Drug Evaluation and Research. Dimethyl fumarate pharmacology review 2012. www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2013\/204063Orig1s000PharmR.pdf. Published February 8 2013. Accessed April 4 2019."},{"issue":"5","key":"e_1_3_1_24_2","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab","volume":"117","author":"Chakravarty EF","year":"2011","unstructured":"Chakravarty EF Murray ER Kelman A Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011;117(5):1499\u20131506. doi:10.1182\/blood-2010-07-295444.","journal-title":"Blood"},{"key":"e_1_3_1_25_2","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000453"},{"issue":"20","key":"e_1_3_1_26_2","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1212\/WNL.0000000000003331","article-title":"Rituximab in multiple sclerosis a retrospective observational study on safety and efficacy","volume":"87","author":"Salzer J","year":"2016","unstructured":"Salzer J Svenningsson R Alping P. Rituximab in multiple sclerosis a retrospective observational study on safety and efficacy. Neurology 2016;87(20):2074\u20132081. doi:10.1212\/WNL.0000000000003331.","journal-title":"Neurology"},{"key":"e_1_3_1_27_2","volume-title":"Rituxan (rituximab) [package insert]","year":"1997","unstructured":"Rituxan (rituximab) [package insert]. South San Francisco, CA; Biogen and Genentech, Inc; 1997."},{"key":"e_1_3_1_28_2","unstructured":"Vukusic S Hoffmann F Wray S. An update on pregnancy outcomes following ocrelizumab treatment in patients with multiple sclerosis and other autoimmune diseases. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Online Library 2017. onlinelibrary.ectrims-congress.eu\/ectrims\/2017\/ACTRIMS-ECTRIMS2017\/200365\/sandra.vukusic.an.update.on.pregnancy.outcomes.following.ocrelizumab.treatment.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dpregnancy+outcomes+ocrelizumab. Accessed April 4 2019."},{"key":"e_1_3_1_29_2","volume-title":"Ocrevus (ocrelizumab) [package insert]","year":"2017","unstructured":"Ocrevus (ocrelizumab) [package insert]. South San Francisco, CA: Genentech, Inc; 2017."},{"key":"e_1_3_1_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000000137"},{"key":"e_1_3_1_31_2","volume-title":"Pregnancy outcomes after exposure to fingolimod and in the general population. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Online Library 2015","author":"Geissb\u00fchler Y","unstructured":"Geissb\u00fchler Y Koren G Wang H. Pregnancy outcomes after exposure to fingolimod and in the general population. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Online Library 2015. onlinelibrary.ectrims-congress.eu\/ectrims\/2015\/31st\/115534\/yvonne.geissbhler.pregnancy.outcomes.after.exposure.to.fingolimod.and.in.the.html?f=listing%3D0%2Abrowseby%3D8%2Asortby%3D1%2Asearch%3Dpregnancy+outcomes+fingolimod. Accessed April 4, 2019."},{"key":"e_1_3_1_32_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-018-0883-2"},{"key":"e_1_3_1_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318228bec5"},{"issue":"10","key":"e_1_3_1_34_2","first-page":"e832","article-title":"Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks","volume":"90","author":"Portaccio E","year":"2018","unstructured":"Portaccio E Moiola L Martinelli V. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks. Neurology 2018;90(10):e832\u2013e839. doi:10.1212\/WNL.0000000000005068.","journal-title":"Neurology"},{"key":"e_1_3_1_35_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31821e7c8a"},{"key":"e_1_3_1_36_2","volume-title":"Disease activity and disability after Natalizumab (NTZ) withdrawal due to planning a pregnancy in women with multiple sclerosis","author":"Esters N","unstructured":"Esters N Spicher C Thiel S. Disease activity and disability after Natalizumab (NTZ) withdrawal due to planning a pregnancy in women with multiple sclerosis. Poster presented at: 70th American Academy of Neurology Annual Meeting; April 21\u201327, 2018; Los Angeles, CA."},{"key":"e_1_3_1_37_2","volume-title":"Disease activity during pregnancy after Fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis","author":"Hemat S","unstructured":"Hemat S Houtschens M Vidal-Jordana A. Disease activity during pregnancy after Fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis. Poster presented at: 70th American Academy of Neurology Annual Meeting; April 21\u201327, 2018; Los Angeles, CA."},{"key":"e_1_3_1_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/ana.24651"},{"key":"e_1_3_1_39_2","volume-title":"Disease activity during pregnancy after fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Online Library 2018","author":"Hemat S","unstructured":"Hemat S. Disease activity during pregnancy after fingolimod withdrawal due to planning a pregnancy in women with multiple sclerosis. European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Online Library 2018. onlinelibrary.ectrims-congress.eu\/ectrims\/2018\/ectrims-2018\/231956\/spalmai.hemat.disease.activity.during.pregnancy.after.fingolimod.withdrawal.html?f=menu%3D14%2Abrowseby%3D8%2Asortby%3D2%2Amedia%3D3%2Aspeaker%3D680653. Accessed April 4, 2019."},{"issue":"1","key":"e_1_3_1_40_2","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12883-016-0674-4","article-title":"Evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry: a global, observational, follow-up study","volume":"16","author":"Friend S","year":"2016","unstructured":"Friend S Richman S Bloomgren G. Evaluation of pregnancy outcomes from the Tysabri (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol 2016;16(1):150. doi:10.1186\/s12883-016-0674-4.","journal-title":"BMC Neurol"},{"key":"e_1_3_1_41_2","volume-title":"Rituximab following natalizumab withdrawal in relapsing remitting multiple sclerosis","author":"Beaber BE","unstructured":"Beaber BE Mallari G Le D Langer-Gould AM. Rituximab following natalizumab withdrawal in relapsing remitting multiple sclerosis. Poster presented at 2014 Joint ACTRIMS-ECTRIMS Meeting; September 10\u201313, 2014; Boston, MA."},{"key":"e_1_3_1_42_2","unstructured":"Gilenya (fingolimod) [package insert]. East Hanover NJ; Novartis; 2019."},{"issue":"11","key":"e_1_3_1_43_2","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1093\/brain\/awv260","article-title":"Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis","volume":"138","author":"Iaffaldano P","year":"2015","unstructured":"Iaffaldano P Lucisano G Pozzilli C. Fingolimod versus interferon beta\/glatiramer acetate after natalizumab suspension in multiple sclerosis. Brain 2015;138(pt 11):3275\u20133286. doi:10.1093\/brain\/awv260.","journal-title":"Brain"},{"key":"e_1_3_1_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-016-8162-8"},{"key":"e_1_3_1_45_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2018.02.028"},{"key":"e_1_3_1_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2013-306054"},{"issue":"1","key":"e_1_3_1_47_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7812\/TPP\/13-090","article-title":"Immunomodulatory agents and risk of postpartum multiple sclerosis relapses","volume":"18","author":"Beaber BE","year":"2014","unstructured":"Beaber BE Chi MD Brara SM. Immunomodulatory agents and risk of postpartum multiple sclerosis relapses. Perm J 2014;18(1):9\u201313. doi:10.7812\/TPP\/13-090.","journal-title":"Perm J"},{"issue":"2","key":"e_1_3_1_48_2","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1089\/bfm.2011.0044","article-title":"Transfer of interferon \u03b2-1a into human breastmilk","volume":"7","author":"Hale TW","year":"2012","unstructured":"Hale TW Siddiqui AA Baker TE. Transfer of interferon \u03b2-1a into human breastmilk. Breastfeed Med 2012;7(2):123\u2013125. doi:10.1089\/bfm.2011.0044.","journal-title":"Breastfeed Med"},{"key":"e_1_3_1_49_2","first-page":"6527458","article-title":"Management of multiple sclerosis in the breastfeeding mother","volume":"2016","author":"Almas S","year":"2016","unstructured":"Almas S Vance J Baker T Hale T. Management of multiple sclerosis in the breastfeeding mother. Mult Scler Int 2016;2016:6527458. doi:10.1155\/2016\/6527458.","journal-title":"Mult Scler Int"},{"issue":"2","key":"e_1_3_1_50_2","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1177\/0890334414566237","article-title":"Transfer of natalizumab into breast milk in a mother with multiple sclerosis","volume":"31","author":"Baker TE","year":"2015","unstructured":"Baker TE Cooper SD Kessler L Hale TW. Transfer of natalizumab into breast milk in a mother with multiple sclerosis. J Hum Lact 2015;31(2):233\u2013236. doi:10.1177\/0890334414566237.","journal-title":"J Hum Lact"},{"issue":"3","key":"e_1_3_1_51_2","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.gastro.2018.05.040","article-title":"Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development","volume":"155","author":"Matro R","year":"2018","unstructured":"Matro R Martin CF Wolf D. Exposure concentrations of infants breastfed by women receiving biologic therapies for inflammatory bowel diseases and effects of breastfeeding on infections and development. Gastroenterology 2018;155(3):696\u2013704. doi:10.1053\/j.gastro.2018.05.040.","journal-title":"Gastroenterology"},{"issue":"6","key":"e_1_3_1_52_2","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1093\/rheumatology\/kex039","article-title":"Low level of Rituximab in human breast milk in a patient treated during lactation","volume":"56","author":"Bragnes Y","year":"2017","unstructured":"Bragnes Y Boshuizen R de Vries A Lexberg A Ostensen M. Low level of Rituximab in human breast milk in a patient treated during lactation. Rheumatology (Oxford) 2017;56(6):1047\u20138. doi:10.1093\/rheumatology\/kex039.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"e_1_3_1_53_2","doi-asserted-by":"crossref","first-page":"442","DOI":"10.3390\/nu3040442","article-title":"Perspectives on immunoglobulins in colostrum and milk","volume":"3","author":"Hurley WL","year":"2011","unstructured":"Hurley WL Theil PK. Perspectives on immunoglobulins in colostrum and milk. Nutrients 2011;3(4):442\u2013474. doi:10.3390\/nu3040442.","journal-title":"Nutrients"},{"issue":"1","key":"e_1_3_1_54_2","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cgh.2017.08.041","article-title":"Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines","volume":"16","author":"Beaulieu DB","year":"2018","unstructured":"Beaulieu DB Ananthakrishnan AN Martin C. Use of biologic therapy by pregnant women with inflammatory bowel disease does not affect infant response to vaccines. Clin Gastroenterol Hepatol 2018;16(1):99\u2013105. doi:10.3390\/nu3040442.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"e_1_3_1_55_2","doi-asserted-by":"publisher","DOI":"10.1177\/1352458517717806"},{"issue":"2","key":"e_1_3_1_56_2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.hoc.2011.01.005","article-title":"Microangiopathic disorders in pregnancy","volume":"25","author":"Pels SG","year":"2011","unstructured":"Pels SG Paidas MJ. Microangiopathic disorders in pregnancy. Hematol Oncol Clin North Am 2011;25(2):311\u2013322, viii. doi:10.1016\/j.hoc.2011.01.005.","journal-title":"Hematol Oncol Clin North Am"},{"issue":"9","key":"e_1_3_1_57_2","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2016.12126","article-title":"Association between MRI exposure during pregnancy and fetal and childhood outcomes","volume":"316","author":"Ray JG","year":"2016","unstructured":"Ray JG Vermeulen MJ Bharatha A. Association between MRI exposure during pregnancy and fetal and childhood outcomes. JAMA 2016;316(9):952\u2013961. doi:10.1001\/jama.2016.12126.","journal-title":"JAMA"},{"issue":"4","key":"e_1_3_1_58_2","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.mric.2017.06.010","article-title":"Safety of contrast material use during pregnancy and lactation","volume":"25","author":"Puac P","year":"2017","unstructured":"Puac P Rodr\u00edguez A Vallejo C. Safety of contrast material use during pregnancy and lactation. Magn Reson Imaging Clin N Am 2017;25(4):787\u2013797. doi:10.1016\/j.mric.2017.06.010.","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"e_1_3_1_59_2","unstructured":"Provigil (modafinil) [package insert]. Frazer PA: Cephalon Inc; 2007."},{"issue":"8","key":"e_1_3_1_60_2","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1136\/jnnp-2012-302235","article-title":"Increased risk of multiple sclerosis relapse after in vitro fertilisation","volume":"83","author":"Michel L","year":"2012","unstructured":"Michel L Foucher Y Vukusic S. Increased risk of multiple sclerosis relapse after in vitro fertilisation. J Neurol Neurosurg Psychiatry 2012;83(8):796\u2013802. doi:10.1136\/jnnp-2012-302235.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"e_1_3_1_61_2","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s11845-008-0265-5","article-title":"Successful pregnancy after rituximab in a women with recurrent in vitro fertilisation failures and anti-phospholipid antibody positive","volume":"178","author":"Ng CT","year":"2009","unstructured":"Ng CT O'Neil M Walsh D. Successful pregnancy after rituximab in a women with recurrent in vitro fertilisation failures and anti-phospholipid antibody positive. Ir J Med Sci 2009;178(4):531\u2013533. doi:10.1007\/s11845-008-0265-5.","journal-title":"Ir J Med Sci"},{"issue":"9","key":"e_1_3_1_62_2","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/1744666X.2016.1178573","article-title":"Current status and future prospects for the treatment of antiphospholipid syndrome","volume":"12","author":"Al Marzooqi A","year":"2016","unstructured":"Al Marzooqi A Leone A Al Saleh J Khamashta M. Current status and future prospects for the treatment of antiphospholipid syndrome. Expert Rev Clin Immunol 2016;12(9):927\u2013935. doi:10.1080\/1744666X.2016.1178573.","journal-title":"Expert Rev Clin Immunol"}],"container-title":["Continuum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00132979-201906000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,10]],"date-time":"2025-07-10T13:59:24Z","timestamp":1752155964000},"score":1,"resource":{"primary":{"URL":"https:\/\/continuum.aan.com\/doi\/10.1212\/CON.0000000000000745"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":61,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1212\/CON.0000000000000745"],"URL":"https:\/\/doi.org\/10.1212\/con.0000000000000745","relation":{},"ISSN":["1080-2371","1538-6899"],"issn-type":[{"value":"1080-2371","type":"print"},{"value":"1538-6899","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}